These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25096864)

  • 1. Bisphosphonate use in children with pediatric osteoporosis and other bone conditions.
    Szalay EA
    J Pediatr Rehabil Med; 2014; 7(2):125-32. PubMed ID: 25096864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
    Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
    J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid improves bone mineral density in pediatric spinal cord injury.
    Ooi HL; Briody J; McQuade M; Munns CF
    J Bone Miner Res; 2012 Jul; 27(7):1536-40. PubMed ID: 22437628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Image assessment of the treatment effect on osteoporosis: bisphosphonates].
    Sone T
    Clin Calcium; 2011 Jul; 21(7):1041-6. PubMed ID: 21719985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates for the prevention and treatment of osteoporosis.
    Maraka S; Kennel KA
    BMJ; 2015 Sep; 351():h3783. PubMed ID: 26333528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis.
    Blair MM; Carson DS; Barrington R
    J Fam Pract; 2000 Sep; 49(9):839-48. PubMed ID: 11032210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment strategy of osteoporosis after the bisphosphonates discontinuation.].
    Soen S
    Clin Calcium; 2017; 27(2):273-280. PubMed ID: 28123130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate treatment of pediatric bone disease.
    Speiser PW; Clarson CL; Eugster EA; Kemp SF; Radovick S; Rogol AD; Wilson TA;
    Pediatr Endocrinol Rev; 2005 Dec; 3(2):87-96. PubMed ID: 16361982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis.
    Simm PJ; Johannesen J; Briody J; McQuade M; Hsu B; Bridge C; Little DG; Cowell CT; Munns CF
    Bone; 2011 Nov; 49(5):939-43. PubMed ID: 21820091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Measurement of bone mineral density is unnecessary for monitoring of bisphosphonate treatment].
    Nishida A; Ito M
    Clin Calcium; 2011 Jan; 21(1):120-3. PubMed ID: 21187605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Once-weekly teriparatide treatment on osteoporosis].
    Nakano T
    Clin Calcium; 2014 Jan; 24(1):100-5. PubMed ID: 24369286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials.
    Hald JD; Evangelou E; Langdahl BL; Ralston SH
    J Bone Miner Res; 2015 May; 30(5):929-33. PubMed ID: 25407702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical review 1: Bisphosphonate use in childhood osteoporosis.
    Bachrach LK; Ward LM
    J Clin Endocrinol Metab; 2009 Feb; 94(2):400-9. PubMed ID: 19033370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of the bone mineral density investigation through measuring of peripheral dual-energetic x-ray absorption in prevention of fractures in children with osteogenesis imperfecta].
    Saganelidze KhZ
    Georgian Med News; 2005 Mar; (120):61-4. PubMed ID: 15855703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of osteoporosis treatment efficacy by bone mass measurement].
    Miki T; Tomiyoshi Y
    Clin Calcium; 2004 Dec; 14(12):19-26. PubMed ID: 15577169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteodensitometry in healthy postmenopausal women.
    Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
    Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC
    Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis].
    Chapurlat R; Meunier PJ
    Rev Chir Orthop Reparatrice Appar Mot; 1998 Nov; 84(8):743-51. PubMed ID: 10192126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis.
    Hodsman A; Adachi J; Olszynski W
    CMAJ; 1996 Oct; 155(7):945-8. PubMed ID: 8837544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.